Journal
IMMUNOLOGY LETTERS
Volume 216, Issue -, Pages 51-62Publisher
ELSEVIER
DOI: 10.1016/j.imlet.2019.10.002
Keywords
Immunotherapy; TCR engineered T cells; Solid cancers
Categories
Funding
- Shenzhen Peacock Plan [KQTD20130416114522736]
- Shenzhen Basic Research Program [JCYJ20170412102821202, JCYJ20180507182902330]
- Special Funds for Dapeng New District Industry Development [KY20150116]
- Natural Science Foundation of Guangdong Province [2016A030313238]
Ask authors/readers for more resources
Adoptive transfer of T cells genetically engineered with chimeric antigen receptors (CAR-T cells) have proven to be highly effective for treating CD19(+) B cell-derived hematologic malignancies. However, due to the lack of ideal tumor surface antigens, CAR-T cell therapy has limited success in treating solid tumors. T cells genetically engineered with T cell receptors (TCR-T cells) recognize intracellular and cell-surface antigens in the context of major histocompatibility complex (MHC) presentation and thus have the potential to access much more target antigens than CAR-T cells, providing great promise in treating solid tumors. There is an increasing interest in the application of TCR-T cell therapy for solid tumors, and fifty-six clinical trials are undergoing worldwide to confirm its validity. In this review, we summarize the recent progress in clinical studies of TCR-T cell therapy, describe strategies in the preparation and characterization of TCR-T cells, focusing on antigen selection, TCR isolation and methods to further enhance the potency of adoptively transferred cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available